NCT03394781

A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

A Randomized, Open-label, Phase 2 Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC)

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Durect · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This is a research trial testing DUR-928 (an experimental medication). The purpose of the trial is to assess whether treatment with DUR-928 has any effect on the treatment of Primary Sclerosing Cholangitis (PSC). This trial will also assess safety (side effects).

Conditions

• Primary Sclerosing Cholangitis

Interventions

Type	Name	Description
DRUG	DUR-928	oral suspension daily for 28 days

Timeline

• Start date: 2018-01-22
• Primary completion: 2019-01-31
• Completion: 2019-01-31
• First posted: 2018-01-09
• Last updated: 2022-10-17
• Results posted: 2022-10-17

Locations

4 sites across 1 country: United States

Regulatory

• FDA-regulated drug study